For example, immune checkpoint inhibitors represented by the anti-PD-1/PD-L1 pathway have achieved the most outstanding curative effect in the treatment of CRC with deficient mismatch repair (dM-MR) or microsatellite instability-high (MSI-H) and have been used for the second-line treatment (68). Here, CD274 is linked to colorectal carcinoma.